Los Angeles – The repeated use of oral CBD products is not associated with liver abnormalities, including increased production of certain liver enzymes, according to observational data published in the journal Cannabis and Cannabinoid Research.
A team of researchers at the University of Buffalo and the University of California at Los Angeles assessed the effect of oral CBD products on liver function in a cohort of nearly 1500 healthy volunteers. The subjects consumed the products for a minimum of 30 days.
No link between CBD and liver abnormalities
Laboratory tests have found no association between the use of CBD products and liver abnormalities. In particular, the authors identified no association between the daily dose of CBD and ALT (alanine transaminase — an enzyme usually found in the liver) levels. Elevated levels of ALT in the blood may indicate liver disease.
Previous onderzoeken on the influence of CBD on the liver have yielded inconsistent results. While some studies have theorized that CBD products may adversely affect the liver's ability to effectively metabolize certain prescription medications, others have reported few, if any, changes in liver function. Other studies have shown an inverse association between cannabis use and certain liver diseases, including cirrhosis and fibrosis.
The full text of the study, “Observed impact of long-term oral cannabidiol consumption on liver function in healthy adults,” appears in the journal “Cannabis and Cannabinoid Research.”
Read more norml.org (Source, EN)
